(C) David C Hay 2009
Drug Testing with Embryonic Stem Cells
– Towards Standards For Assays

David C Hay

September 2009. As stem cell derived models of human liver biology move closer to diagnostic implementation there is an imperative for model standardisation living up to requirements of regulators and pharma industry’s needs (e.g. high throughput of stem cells) …. still not satisfactorily resolved.


Hay DC (2009): Drug Testing with Embryonic Stem Cells – Towards Standards For Assays. Published online September 12, B2Bioworld.com.

If you like to read this article, you can order it here

Individual License 1 Reader :1.50 EUR
Organisation Sharing License < 6 Readers: 4.00 EUR + VAT 7%

•   Article free of advertisement, 3 pages
- Includes experimental data and information on UK's Stem Cells for Safer Medicines

•   Payment via PayPal, or Direct Invoice

Back to section

Related Editorial Articles

Leroy Hood: Some Thoughts on Stem Cell Research

Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

L'Oréal Makes Progress in Stem Cell Research

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Stem Cells – Failings and Deliveries
Hugh Ilyine, longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Triggering Regenerative Functions with Transplanted Cells and Small Molecules
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville

Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Patenting Stem Cells - Behind the Front Stage

Bayer: New Stakes in Stem Cells
Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

System Biology In Search of Good Questions
Walter Kolch on the approach taken by Systems Biology Ireland

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts